Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

Abstract Background Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s disease (AD). In this study, we elucidate the utilit...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yoshiki Niimi, Shorena Janelidze, Kenichiro Sato, Naoki Tomita, Tadashi Tsukamoto, Takashi Kato, Kenji Yoshiyama, Hisatomo Kowa, Atsushi Iwata, Ryoko Ihara, Kazushi Suzuki, Kensaku Kasuga, Takeshi Ikeuchi, Kenji Ishii, Kengo Ito, Akinori Nakamura, Michio Senda, Theresa A. Day, Samantha C. Burnham, Leonardo Iaccarino, Michael J. Pontecorvo, Oskar Hansson, Takeshi Iwatsubo
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-05-01
Col·lecció:	Alzheimer’s Research & Therapy
Matèries:	Blood-based biomarker p-tau217 Amyloid-β Amyloid positron emission tomography
Accés en línia:	https://doi.org/10.1186/s13195-024-01469-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!